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Abstract
Background
Respiratory disease and, specifically, pneumonia, is the major cause of mortality and morbid-
ity in young children. Diagnosis of both pneumonia and asthma in primary care rests princi-
pally on clinical signs, history taking, and bronchodilator responsiveness. This study aimed to
describe clinical practices in diverse global primary care settings concerning differential diag-
nosis of respiratory disease in young children, especially between pneumonia and asthma.
Methods
Health professionals in Greece, Kyrgyzstan, Vietnam, and Uganda were observed during
consultations with children aged 2–59 months, presenting with cough and/or difficult breath-
ing. Data were analyzed descriptively and included consultation duration, practices, diagno-
ses and availability/use of medications and equipment. The study is part of the European
Horizon 2020 FRESH AIR project.
Results
In total, 771 consultations by 127 health professionals at 74 facilities in the four countries
were observed. Consultations were shorter in Vietnam and Uganda (3 to 4 minutes)
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compared to Greece and Kyrgyzstan (15 to 20 minutes). History taking was most compre-
hensive in Greece. Clinical examination was more comprehensive in Vietnam and Kyrgyz-
stan and less in Uganda. Viral upper respiratory tract infections were the most common
diagnoses (41.7% to 67%). Pneumonia was diagnosed frequently in Uganda (16.3% of chil-
dren), and rarely in other countries (0.8% to 2.9%). Asthma diagnosis was rare (0% to
2.8%). Antibiotics were prescribed frequently in all countries (32% to 69%). Short acting β-
agonist trials were seldom available and used during consultations in Kyrgyzstan (0%) and
Uganda (1.8%), and often in Greece (38.9%) and Vietnam (12.6%).
Conclusions
Duration and comprehensiveness of clinical consultations observed in this study seemed
insufficient to guide respiratory diagnosis in young children. Appropriate treatment options
may further not be available in certain studied settings. Actions aiming at educating and rais-
ing professional awareness, along with developing easy-to-use tools to support diagnosis
and a general strengthening of health systems are important goals.
Introduction
Globally, respiratory disease is among the major causes of morbidity and mortality, and young
children are particularly susceptible [1]. Two decades ago, mortality in children under five
years old (under-fives) was twice as high as it is today [2]. As a response, the World Health
Organization (WHO) launched the Integrated Management of Childhood Illness (IMCI)
guidelines [3] as a tool to help health professionals diagnose and treat the main causes of
under-five mortality. IMCI has since been implemented in more than 75 countries [4]. The
guidelines are designed for use in primary care without sophisticated equipment or skills and a
full IMCI assessment takes approximately 8–12 minutes [5].
The main cause of reported mortality in under-fives is pneumonia [2]. Evidence suggests
that mortality from lower respiratory diseases other than pneumonia, e.g. asthma, is frequently
under-reported [6]. Worldwide, diagnosis of pneumonia in primary care rests primarily on
clinical signs [7,8] while diagnosis of asthma mainly depends on history taking and bronchodi-
lator responsiveness [9]. IMCI uses simple clinical signs, such as cough and fast breathing, to
diagnose pneumonia [10]. Empiric antibiotic treatment is recommended if specific criteria are
met. This has led to a concern that pneumonia is over-diagnosed and antibiotics are prescribed
unnecessarily, since IMCI has high sensitivity and low specificity for pneumonia [11]. How-
ever, the spectrum of respiratory diseases with overlapping symptoms in young children
ranges from acute self-limiting viral infections to bacterial infections to non-communicable
diseases [12].
Asthma is the most common non-communicable disease among children, with a global
prevalence of 5.5% to 25% [13]. Cohort studies have shown that asthma symptoms often start
in early childhood [14]. Studies in low- and middle-income countries have documented a high
prevalence of asthma among under-fives diagnosed with pneumonia as defined by IMCI [15–
17]. A study from Uganda indicated that 41% of under-fives admitted with acute respiratory
illness symptoms actually suffered from asthma or other bronchospastic diseases [18].
Untreated acute asthma may contribute to treatment failure, prolonged illness and pneumo-
nia-attributed mortality [6]. Besides problems with under-diagnosis, there are challenges
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concerning availability of equipment and necessary medication to diagnose and treat asthma
in low-resource settings [19].
Therefore, it is essential that clinical assessment of children with respiratory symptoms is
sufficient to elicit signs and symptoms that can help clinicians differentiate between common
lower respiratory conditions, like pneumonia and asthma, requiring urgent treatment, versus
self-limiting viral infections for which supportive care is most important.
The purpose of this study was to describe clinical practices of health professionals in pri-
mary care settings with diverse socio-economic backgrounds with regard to differential diag-
nosis of respiratory disease, especially between pneumonia and asthma, for children
presenting with respiratory symptoms. Our secondary objective was to evaluate the availability
of equipment and medications for asthma at the participating health facilities.
Materials and methods
This descriptive study is part of the European Horizon2020 programme FRESH AIR (https://
www.theipcrg.org/freshair) [20]. Data were collected at first line health facilities in Crete,
Greece (December 2016-March 2017); Naryn and Chui regions, Kyrgyzstan (April-November
2016); Long An province, Vietnam (December 2016); and Jinja district, Uganda (August-Sep-
tember 2016) (Fig 1). Facilities ranged from referral hospitals also serving as entry point
(Greece, Vietnam, Uganda) to health centers (Greece, Kyrgyzstan, Uganda) and single-person
manned rural facilities (Kyrgyzstan, Vietnam, Uganda).
Data were collected using three approaches: 1) direct observations of clinical consultations
between health professionals and under-fives to document comprehensiveness of consulta-
tions, practices and diagnoses, 2) exit interviews with caregivers to obtain background infor-
mation on the child’s disease and on the present consultation, 3) a short follow-up telephone
call with caregivers 5 days after the consultation. This methodology was adapted from WHO’s
Health Facility Survey, designed to assess the quality of provided healthcare [21]. We also col-
lected data on human resources, availability of medications and equipment of the participating
facilities as detailed in the Health Facility Survey: The health facility administrator filled out a
health facility survey form concerning beds, human resources, and medication available in col-
laboration with the research staff at the first visit to the health facility Research staff then
walked through the facility and noted the availability of equipment.
Health professionals were eligible if routine care of children was part of their official duties.
They included pediatricians (Greece, Vietnam), general practitioners and nurses (Kyrgyzstan,
Vietnam, Uganda), as well as clinical officers with three years of medical training (Kyrgyzstan,
Uganda). Children were screened for inclusion at registration desks, triage areas, or waiting
lines prior to consultation. Inclusion criteria for children were age of two to 59 months and
presenting complaint of cough and/or difficult breathing according to the caregiver.
Upper respiratory tract infections were categorized as “viral infection” if the health profes-
sional diagnosed the child with acute respiratory tract infection (ARI), cold, coryza, flu, naso-
pharyngitis, pharyngitis, respiratory tract infection (RTI), upper respiratory tract infection
(URTI), or viral infection. If children received more than one diagnosis, a primary diagnosis
was assigned in the following order: asthma, pneumonia, bronchitis, tonsillitis, bronchiolitis,
malaria, viral infections. This order was decided by JK and AP taking specificity of symptoms
and treatment into account.
All study tools were pilot tested in each country and adapted to fit local contexts. Data were
collected by specially trained local staff, including medical doctors, nurses, clinical officers,
medical researchers, and public health graduates. Data were typed into REDCap (Research
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Electronic Data Capture) [22] and exported to STATA Version 15.1 (Stata Corp, Texas, USA)
for analysis. Results are summarized using descriptive statistics.
The study was approved by the 7th Health Region of Crete, Hellenic Republic Ministry of
Health; Ethics Committee of National Center of Cardiology and Internal Medicine, Bishkek,
Kyrgyzstan; IRB committee of University of Medicine and Pharmacy, HCMC, Vietnam;
Mulago Hospital Research and Ethics Committee (MREC), the Uganda National Council of
Science and Technology, the Leiden University Medical Centre ethical review board, The
Netherlands, and The Danish Data Protection Agency (J.nr. 2017-41-5051). All health
Fig 1. Map of countries participating in the study and key health system indicators.
https://doi.org/10.1371/journal.pone.0221389.g001
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professionals and caregivers of children signed informed consent forms for participation in
the study according to both international and local regulations.
Results
In total, 771 clinical consultations made by 127 health professionals at 74 health facilities were
observed. The median number of observations per health professional was 4 (IQR 1–7) and
the median number of observations performed at each facility was 4 (IQR 2–8). In Kyrgyzstan
and Uganda, approximately 80% of consultations were performed by nurses and clinical offi-
cers (Table 1, Fig 2).
The proportion of children presenting with respiratory symptoms was 43% to 50% and the
duration of symptoms prior to consultation was similar in all countries. Caregivers and chil-
dren were younger in Uganda and Kyrgyzstan. Approximately 10–15% (Greece, Kyrgyzstan,
Uganda) to 40% (Vietnam) of children had five or more previous attendances for respiratory
symptoms. In Vietnam, one in four children had 10 or more (Table 2).
Consultations lasted a median of 5 minutes (IQR 3–20). They were shorter in Vietnam and
Uganda (3 to 4 minutes) in contrast to Greece and Kyrgyzstan (15 to 20 minutes). History tak-
ing and clinical examination varied greatly. In all countries, several core respiratory symptoms
were rarely asked and in Uganda, clinical examination often did not include basic assessment
of respiratory disease signs. Questions on former respiratory illnesses were rarely asked by
health professionals. Present symptoms typical of asthma, such as difficult breathing, were
often asked in Greece (52�8%), but seldom in Kyrgyzstan, Uganda, and Vietnam. Likewise,
questions on wheeze or noisy breathing were mostly absent in all countries (Table 3).
Viral URTIs were most common in all countries, accounting for about half of all diagnoses.
Pneumonia was diagnosed frequently in Uganda (16.3%), but rarely in the other countries
(0.8% to 2.5%). Bronchitis diagnoses were often used in all countries (15.1% to 19.7%), except
Table 1. Characteristics of health professionals observed during consultations with children aged 2–59 months with respiratory symptoms in low-, middle-, and
high-income, primary care settings.
Greecea
n observations = 72
Kyrgyzstanb
n observations = 239
Vietnamc
n observations = 239
Ugandad
n observations = 221
Total
N = 771
Number of individual health professionals observed 7 62 9 49 127
Number of observations per health professional, median
(IQR)
6 (3–19) 3 (2–5) 12 (10–28) 3 (1–8) 4 (1–7)
Consultations performed by, n (%)
Pediatrician 72 (100) 8 (3.4) 208 (87.0) 0 288
(37.3)
Internal Medicine Doctor 0 0 10 (4.2) 0 10 (1.3)
General Doctor 0 36 (15.1) 21 (8.8) 20 (9.1) 77 (10.0)
Anaesthesiologist 0 0 0 16 (7.2) 16 (2.1)
Clinical Officer 0 104 (43.5) 0 145 (65.6) 249
(32.3)
Nurse 0 90 (37.7) 0 30 (13.6) 120
(15.6)
Information on class of health professional missing for
a: 1 observation
b: 1 observation
c: 0 observations
d:10 observations
https://doi.org/10.1371/journal.pone.0221389.t001
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Uganda (0.9%). Asthma diagnosis was rare (0% to 2.8%) and malaria was only encountered in
Uganda (16.3%) (Table 4, Fig 3).
Antibiotics were prescribed frequently in all countries (32% to 67%), namely for viral
URTIs (22.9% to 63.8% of cases) and bronchitis (46.2% to 88.9%). They were prescribed for 14
out of 36 (Uganda) to one out of one (Greece) cases diagnosed with pneumonia and to all
cases of tonsillitis (Table 4).
Short acting β-agonists were often prescribed for children diagnosed with bronchiolitis,
bronchitis, and asthma in Greece and Vietnam, but never in Kyrgyzstan and Uganda
(Table 4). Short acting β-agonist trials were used in Greece (38.9% of consultations) and Viet-
nam (12.6%) but almost never in Kyrgyzstan and Uganda. Short acting β-agonist trials had a
positive response in approximately half of cases, according to provider report. Inhaled short
acting β-agonists were prescribed for two in five children in Greece and for one in five children
in Vietnam but never in Kyrgyzstan or Uganda. In Kyrgyzstan and Vietnam, antivirals and
cough medicines were prescribed frequently (30.5% and 75.3%) but rarely in Greece and
Uganda (Table 5).
Children were referred to a higher level of care in 3.6% (Kyrgyzstan) to 10% (Uganda) of
cases. Cough and/or difficult breathing were still present in 0.8% (Kyrgyzstan) to 17% (Greece)
Fig 2. Number of consultations by class of health professional.
https://doi.org/10.1371/journal.pone.0221389.g002
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at five days follow-up. In Greece, 9.7% of children had been admitted to hospital at follow-up,
1.7% in Kyrgyzstan, 3.7% in Vietnam, and 2.8% in Uganda. Mortality at follow-up was 0% in
Greece, Kyrgyzstan, and Vietnam, and 0.9% in Uganda: One child aged four months present-
ing with fever, cough and vomiting, diagnosed with a bacterial infection and one child aged 48
months presenting with fever, cough, chest pain and loss of appetite, diagnosed with an ARI.
Both children were assigned to home treatment. The chest of the four months old child was
not exposed. During the exit interview, the mother reported: “Treatment given is always the
same. He normally gets difficult breathing and also wheezes at night and coughs more at night
than at day”.
In Greece, Kyrgyzstan, and Uganda, most surveyed facilities were small, with limited per-
sonnel and either no, or a few beds for pediatric care. All facilities had electricity, while oxygen
and nebulizers were always available in Greece and Vietnam. With a few exceptions, spacers
were only available in Greece. In Greece and Vietnam, all facilities had access to nebulized
short acting β-agonists. Metered dose inhaler short acting β-agonists were often available in
rural clinics in Greece and Kyrgyzstan and at the referral level in Vietnam (Table 6).
Discussion
Main findings
To our knowledge, this is the first study to describe diagnostic and treatment practices related
to ARI in under-fives across primary care settings in high-, middle-, and low-income countries
with diverse socio-economic and cultural backgrounds. We documented variations in consul-
tation routines, medication availability and frequency of pneumonia diagnoses, along with
very low rates of asthma diagnoses and high rates of unnecessary antibiotic prescriptions.
Table 2. Characteristics of children aged 2–59 months observed during consultations for respiratory symptoms in low-, middle-, and high-income, primary care
settings.
Greece Kyrgyzstan Vietnam Uganda Total
Screening and inclusion
Number screened for cough and/or difficult breathing, n 166 494 480 486 1626
Number included in study and observed, n (% of screened) 72 (43.4) 239 (48.4) 239 (49.8) 221 (45.5) 771 (47.4)
Demographic characteristics
Maternal age in years, mean (SD) 32�5 (5.8) [1] 29�1 (6.0) [4] 32�3 (6.7) [6] 26�4 (5.1) [9] 29�6 (6.4) [20]
Child age in months, median (IQR) 42 (23.�5–54) [0] 26 (14–38) [0] 31 (19–46) [0] 18 (7–30) [8] 26 (13–42) [8]
Child sex, n female (%) 31 (43.1) [0] 114 (47.7) [0] 106 (44.4) [0] 104 (47.1) [20] 355 (46�0) [20]
Clinical characteristics
Duration of symptoms prior to consultation in days, median (IQR) 3 (2–5) [2] 4 (2–5) [6] 3 (2–5) [95] 3 (2–7) [73] 3 (2–5) [176]
Previous attendance for cough/difficult breathing, n (%) 43 (59.7) [1] 156 (65.3) [4] 186 (77.8) [2] 184 (83.3) [4] 596 (73.8) [11]
Number of previous attendances, n (%):
1 or 2 28 (38.9) 105 (43.9) 38 (15.9) 53 (24.0) 224 (29.1)
3 or 4 7 (9.7) 29 (12.1) 48 (20.1) 59 (26.7) 143 (18.6)
5 to 9 6 (8.3) 21 (8.8) 34 (14.2) 31 (14.0) 92 (11.9)
10 or more 1 (1.4) 2 (0.8) 57 (23.9) 4 (1.8) 64 (8.3)
No data on previous attendances 30 (41.7) 82 (34.3) 62 (25.9) 74 (33.5) 248 (32.2)
Breathing difficulty at follow-up, n (%) 12 (16.7) [5] 2 (0.8) [8] 12 (5.0) [31] 23 (10.4) [90] 49 (6.7) [134]
Follow-up time in days, median (IQR) 5 (5–5) 5 (5–5) 5 (5–5) 5 (5–5) 5 (4–8)
Numbers in [] represent data that is either missing or question not asked by healthcare professional.
https://doi.org/10.1371/journal.pone.0221389.t002
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The level of history taking and clinical examination in Kyrgyzstan, Vietnam, and Uganda is
comparable to past findings from other low- and middle-income countries in South-east Asia,
South America, and Africa, [5,23,24] indicating that there is still much room for improvement
in this regard. In a study from Tanzania, longer consultations were associated with better qual-
ity of clinical assessment [23]. In Greece and Kyrgyzstan, there was sufficient time for a full
IMCI assessment, whereas in Uganda and Vietnam time spent was even shorter than in other
low-resource countries.5
As expected, most children were diagnosed with viral URTIs, yet different diagnostic pat-
terns were observed across countries. For example, pneumonia was frequently diagnosed in
Uganda and rarely in the other countries, while the opposite applied to bronchitis. This may
reflect variations in incidence, health seeking behavior, diagnostic criteria, or health profes-
sionals’ knowledge or practices. Studies have indicated that the incidence of pneumonia is
higher in low-income countries compared to high-income countries [25]. However, it is nota-
ble that these estimates were obtained using the WHO criteria for clinical pneumonia, while it
has been shown that in low- and middle-income countries, approximately half of children
diagnosed with pneumonia using the same criteria, have asthma or other bronchospastic dis-
eases [15, 17].
The IMCI guidelines suggest a short-acting β-agonist trial to distinguish between pneumo-
nia and asthma. In most Ugandan sites, however, neither inhaled short-acting β-agonists nor
spacers were available. In Kyrgyzstan, inhaled short acting β-agonists were reported to be
Table 3. History taking and clinical examination of children aged 2–59 months with respiratory symptoms during consultations in low-, middle-, and high-income,
primary care settings.
Greece
n = 72
Kyrgyzstan
n = 239
Vietnam
n = 239
Uganda
n = 221
Total
N = 771
Duration of consultation in minutes, median (IQR) 15 (10–30) [14] 20 (20–25) [0] 3 (2–3) [0] 4 (3–4) [4] 5 (3–20) [18]
Core respiratory symptoms asked, n (%)
History of present illness
Fever 63 (87.5) [1] 118 (49.4) [4] 131 (54.8) [0] 75 (34.9) [6] 387 (50.2) [11]
Difficult breathing during this illness 38 (52.8) [1] 36 (15.1) [4] 6 (2.5) [0] 16 (7.2) [7] 96 (12.5) [12]
Wheezing during this illness 6 (8.3) [0] 0 (0) [0] 26 (10.9) [1] 5 (2.3) [7] 37 (4.8) [8]
Noisy breathing 7 (9.7) [1] 10 (4.2) [5] 0 (0) [0] 8 (3.6) [6] 25 (3.2) [12]
Night or early morning cough 25 (34.7) [1] 34 (14.2) [4] 15 (6.3) [0] 15 (6.8) [7] 89 (11.5) [12]
Past medical history
Recurrent difficult breathing 12 (16.7) [1] 0 (0) [5] 0 (0) [0] 5 (2.3) [7] 17 (2.2) [13]
Recurrent cough 33 (45.8) [0] 0 (0) [4] 10 (4.2) [0] 13 (5.9) [9] 56 (7.3) [13]
At least one core respiratory symptom, except fever 53 (73.6) [0] 50 (20.9) [4] 48 (20.1) [0] 34 (15.4) [6] 185 (24.0) [11]
History of triggers 5 (6.9) [1] 0 (0) [0] 0 (0) [12] 7 (3.2) [5] 12 (1.6) [18]
Child or family history of asthma and/or allergy 33 (45.8) [1] 106 (44.4) [4] 4 (1.7) [0] 17 (7.7) [3] 160 (20.8) [8]
Previous medications 48 (66.7) [0] 0 (0) [0] 67 (28.0) [0] 44 (19.9) [4] 159 (20.6) [4]
Clinical examination performed, n (%)
Chest exposed 72 (100) [0] 219 (91.6) [4] 222 (92.9) [0] 47 (21.3) [9] 560 (72.6) [13]
Respiratory rate counted 72 (100) [0] 24 (10.0) [6] 60 (25.1) [0] 24 (10.8) [9] 180 (23.3) [15]
Chest wall in-drawing checked for 41 (56.4) [1] 0 (0) [6] 0 (0) [0] 23 (10.4) [16] 64 (8.3) [33]
Stethoscope used 72 (100) [0] 227 (95.0) [4] 219 (91.6) [0] 35 (15.8) [15] 553 (71.7) [19]
Temperature felt or measured 46 (63.9) [0] 100 (41.8) [4] 57 (23.9) [0] 94 (42.5) [8] 297 (38.5) [12]
Referrals to secondary care 5 (6.9) [2] 8 (3.4) [4] 15 (6.3) [5] 22 (10.0) [28] 50 (6.5) [39]
Numbers in [] represent data that is either missing or question not asked by healthcare professional.
https://doi.org/10.1371/journal.pone.0221389.t003
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Table 4. Diagnoses and treatments assigned to children aged 2–59 months presenting with respiratory symptoms in low-, middle-, and high-income, primary care
settings.
n (column %) VURTIc Pneumonia Tonsillitis Bronchitisf Bronchiolitis Asthma Malaria Other
diagnosisd
No
diagnosis
Total
Greece
n = 72
Antibiotics 10 (33.3) 1 (100) 1 (100) 6 (46.2) - - - 2 (40.0) 3 (23.1) 23
(31.9)
Antivirals and cough
medicinea
4 (13.3) - - - - - - - 1 (7.7) 5 (6.9)
SABA 5 (16.7) - - 11 (84.6) 5 (71.4) 2 (100) - - 4 (30.8) 27
(37.5)
Corticosteroidsb 3 (10.0) - - 5 (38.5) 2 (28.6) - - - 3 (23.1) 13
(18.1)
Supportive treatmente 1 (3.3) - - - - - - 1 (20.0) 1 (7.7) 3 (4.2)
No treatment 8 (26.7) - - - - - - 1 (20.0) 2 (15.4) 11
(15.3)
Total (row %) 30 (41.7)
[0]
1 (1.4) [0] 1 (1.4) [0] 13 (18.1)
[0]
7 (9.7) [0] 2 (2.8)
[0]
0 (0) [0] 5 (6.9) [0] 13 (18.1)
[0]
72 [0]
Kyrgyzstan
n = 239
Antibiotics 80 (52.6) 1 (50.0) 9 (100) 28 (59.6) - - - 16 (69.6) - 134
(56.1)
Antivirals and cough
medicinea
71 (46.7) - 2 (22.2) 21 (44.7) - - - 6 (26.1) - 100
(41.8)
SABA - - - - - - - - - -
Corticosteroidsb - - - - - - - - - -
Supportive treatmente - - - - - - - - - -
No treatment 2 (1.3) 1 (50.0) - 1 (2.1) - - - 1 (4.4) 1 (16.7) 6 (2.5)
Total (row %) 152 (63.6)
[0]
2 (0.8) [0] 9 (3.8) [0] 28 (19.7)
[0]
0 (0) [0] 0 (0) [0] 0 (0) [0] 23 (9.6) [0] 6 (2.5) [0] 239 [0]
Vietnam
n = 239
Antibiotics 102 (63.8) 6 (100) 3 (100) 32 (88.9) 12 (70.6) 1 (50.0) - - - 160
(67.0)
Antivirals and cough
medicinea
135 (84.4) 3 (50.0) 2 (66.7) 26 (72.2) 11 (64.7) 1 (50.0) - - - 181
(75.7)
SABA 5 (3.1) 4 (66.7) 1 (33.3) 22 (61.1) 12 (70.6) 1 (50.0) - - - 47
(19.7)
Corticosteroidsb 4 (2.5) 1 (16.7) - 5 (13.9) 3 (17.7) - - - - 13
(5.4)
Supportive treatmente - - - - - - - - - -
No treatment - - - - - - - - - -
Total (row %) 160 (67.0)
[2]
6 (2.5) [0] 3 (1.3) [0] 36 (15.1)
[1]
17 (7.1) [1] 2 (0.8)
[0]
0 (0) [0] 0 (0) [0] 0 (0) [0] 239
[12]
Uganda
n = 221
Antibiotics 22 (22.9) 14 (38.9) - - 4 (57.1) - 20 (55.6) 5 (50.0) 4 (16.0) 73
(33.0)
Antivirals and cough
medicinea
- - - - - - - - - -
SABA - - - - - - - - - -
Corticosteroidsb - - - - - - 1 (2.8) - - 1 (0.5)
Supportive treatmente 44 (45.8) 8 (22.2) - - 3 (42.9) - 9 (25.0) 1 (5.6) 1 (4.0) 66
(29.9)
No treatment - - - - - - - - - -
Total (row %) 96 (43.4)
[0]
36 (16.3)
[0]
0 (0) [0] 2 (0.9) [0] 7 (3.2) [0] 1 (0.5)
[0]
36 (16.3)
[0]
18 (8.1) [0] 25 (11.3)
[0]
221 [0]
(Continued)
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available, but spacers were not. It is worth noting that inhaled short acting β-agonists, inhaled
corticosteroids, and spacers are on the WHO essential medicines list [26]. Interestingly, in the
countries where short acting β-agonist trials were available and used, symptom relief was
observed in relatively high rates, however, only a few cases were diagnosed with asthma.
A recent WHO report identifies unnecessary antibiotic prescriptions among the major
issues to be addressed in order to combat the global health threat of antimicrobial resistance
[27, 28]. In this study, approximately half of children diagnosed with viral URTI were pre-
scribed antibiotics. In the United States, among 5700 children and teenagers presenting with
acute URTI, approximately half received un-indicated antibiotics [29]. Data on the global mag-
nitude of unnecessary antibiotic prescriptions seem scarce [28]. However, the problem is likely
even more pronounced in countries where over the counter sale of antibiotics is not regulated,
an issue not addressed in our study. Qualitative data from Kyrgyzstan and Uganda show that
caregivers often go directly to the pharmacy for repeated episodes of illness with similar symp-
toms to buy the medicine prescribed on the first visit, to save time and money needed for
another consultation (Nantanda et al. manuscript in preparation, authors’ unpublished data).
Thus, an initial inappropriate prescription of antibiotics can snowball into further unnecessary
use, as well as an expectation among caregivers of antibiotic treatment also for viral infections.
Finally, an interesting country-specific finding concerned the use of other antiviral and
cough medications. Most children in Vietnam and many in Kyrgyzstan, were prescribed
mucolytic agents, cough medicines, or antiviral drugs, despite the fact that there is no sufficient
evidence of any effect, particularly in younger children [30] and that such medicines are not
generally recommended due to serious reported side effects [31].
Table 4. (Continued)
n (column %) VURTIc Pneumonia Tonsillitis Bronchitisf Bronchiolitis Asthma Malaria Other
diagnosisd
No
diagnosis
Total
Total
N = 771
Antibiotics 214 (48.9) 22 (48.9) 13 (100) 66 (67.4) 16 (51.6) 1 (20.0) 20 (55.6) 27 (58.7) 7 (15.9) 390
(50.6)
Antivirals and cough
medicinea
210 (48.0) 3 (6.7) 4 (30.8) 47 (48.0) 11 (35.5) 1 (20.0) - 6 (13.0) 1 (2.3) 286
(37.1)
SABA 10 (2.3) 4 (8.9) 1 (7.7) 33 (33.7) 17 (54.8) 3 (60.0) - - 4 (9.1) 74
(9.6)
Corticosteroidsb 7 (1.6) 1 (2.2) - 10 (10.2) 5 (16.1) - 1 (2.8) - 3 (6.8) 27
(3.5)
Supportive treatmente 45 (10.3) 8 (17.8) - - 3 (9.7) - 9 (25.0) 2 (4.4) 2 (4.6) 69
(9.0)
No treatment 10 (2.3) 1 (2.2) - 1 (1.0) - - - 2 (4.4) 3 (6.8) 17
(2.2)
Total (row %) 438 (56.8)
[2]
45 (5.8) [0] 13 (1.7)
[0]
98 (12.7)
[1]
31 (4.0) [1] 5 (0.7)
[0]
36 (4.7)
[0]
46 (6.0) [0] 44 (5.7)
[0]
771
[12]
SABA: Short acting β-agonist, VURTI: Viral upper respiratory tract infection. Numbers in [] represent data that is either missing or question not asked by healthcare
professional.
aIncluding cough medicine.
b Inhaled or oral.
c Consisting of children with the following diagnoses according to health professional report: acute respiratory tract infection, cold, coryza, flu, nasopharyngitis,
pharyngitis, respiratory tract infection, upper respiratory tract infection, viral infection.
d Other diagnoses: e.g. croup, otitis, scarlet fever, stomatitis aphtosa, tracheitis, diarrhea.
e Supportive treatment: e.g. paracetamol, ibuprofen, antihistamines, fluids, and in Uganda also artemether/lumefantrine, mebendazole, vitamin A.
f Including bronchitis diagnoses with a variety of prefixes, e.g. acute, obstructive, allergic.
https://doi.org/10.1371/journal.pone.0221389.t004
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Strengths and limitations
The descriptive design of our study does not allow for statistical comparisons, and our finding
of very diverse problems and settings indicate that generalizations should be done carefully.
Additionally, although we used direct observation of clinical practice instead of self-reporting
to minimize reporting bias, it is possible that health professionals may have performed better
than their standard due to the presence of research staff in the consultations [32]. In a study
from Tanzania, a significant Hawthorne effect was observed under circumstances comparable
Fig 3. Diagnosis assigned to children aged 2–59 months presenting with respiratory symptoms in low-, middle-, and high-income,
primary care settings.
https://doi.org/10.1371/journal.pone.0221389.g003
Table 5. Use and effect of short acting β-agonist trials in children aged 2–59 months presenting with respiratory symptoms in low-, middle-, and high-income, pri-
mary care settings.
Greece, n = 72 Kyrgyzstan, n = 239 Vietnam, n = 239 Ugandaa, n = 221 Total, N = 771
SABA trial performed, n (%) 28 (38.9) - 30 (12.6) 4 (1.8) 62 (8.0)
Positive response to SABA trial, n (%) 18 (64.3) - 10 (33.3) 1 (25.9) 29 (46.8)
SABA: Short acting β-agonist
a: In Uganda, the majority of clinics only had oral SABAs available.
https://doi.org/10.1371/journal.pone.0221389.t005
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to our study, but the effect waned after 10 to 15 consultations [23]. If this finding is generaliz-
able, it has implications for the interpretation of our data, as we observed most health profes-
sionals less than 10 to 15 times.
Furthermore, data were collected by a diverse range of researchers with varying back-
ground, including medical doctors and research assistants. There is a risk of misclassification
when assigning complex acts of clinical consultations into categories on data collection forms
and a thorough knowledge of clinical practice is probably an advantage. It is also likely that
Table 6. Human resources, amenities, equipment and medications available at participating primary care facilities.
At pediatric ward At health facility Availability of amenities and equipment Availability of medication
Country Level Beds Cots Pediatricians MDs COs Nurses Electricity Oxygen Nebulizers Spacers SABA for
nebulizer
MDI
SABA
Oral
SABA
ICS OCS
Greece Rural 0 0 1 19 0 0
Rural 0 0 1 6 0 1
Rural 2 1 1 10 0 3
Rural 1 0 1 8 0 2
Kyrgyzstan Rural 0 0 0 1 0 5
Rural 0 0 0 0 1 0
Rural 0 0 0 0 0 1
Rural 0 0 0 0 0 3
Rural 0 0 0 1 0 3
Rural 0 0 0 0 1 0
Rural 0 0 0 0 1 1
Rural 0 0 0 1 0 5
Rural 0 0 0 0 1 0
Rural 0 0 1 3 0 5
Rural 0 0 0 5 0 10
Rural 0 0 0 0 1 1
Rural 0 0 0 0 1 1
Rural 0 0 0 0 0 1
Rural 0 0 0 2 0 3
Rural 0 0 0 0 1 0
Rural 0 0 0 0 1 1
Rural 0 0 0 2 0 4
Rural 0 0 0 0 1 1
Referral - - - 87 - 270
Referral 15 0 2 0 0 6
Uganda Rural 3 1 0 2 2 2
Rural 2 2 0 2 2 2
Rural 2 0 0 2 2 2
Rural 6 0 0 1 2 2
Rural 0 0 0 0 1 2
Rural 4 2 0 2 3 3
Referral 50 10 2 1 2 4 -
Vietnam Rural 35 4 3 0 2 3
Referral 105 10 10 11 0 33
Answers according to color: Always (dark green); Often (green); Sometimes (yellow); Never (dark red); Yes (light green); No (red) MDs: medical doctors, COs: Clinical
Officers, SABA: Short acting β-agonist, MDI: Metered dose inhaler, ICS: Inhaled corticosteroids, OCS: Oral corticosteroids
https://doi.org/10.1371/journal.pone.0221389.t006
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educational, cultural, and other differences have affected data collection to some extent. How-
ever, each country was visited by representatives of the coordinating team (JK, MSØ, AP, and/
or SR) prior to study initiation and all forms were thoroughly discussed to minimize reporting
differences.
We used a convenience sample of clinical sites, which may have introduced unconsidered
biases in our efforts to represent how care is delivered in the participating countries. We also
focused on public health services, however, there is a possibility that caregivers frequently
bypass the public sector. As such, we may have not identified areas of possible improvement in
the management of children with respiratory disease.
Implications for education, research, health services and policy
Reducing child morbidity and mortality is a core element of the Millennium Development
Goals, however, it seems that there is still much ground for improvement in the spectrum of
childhood respiratory care particularly in low- and middle-income settings. Increasing aware-
ness and education of health professionals and ensuring availability of essential medications
should be among the first steps to combat respiratory misdiagnoses and inappropriate use of
antibiotics.
Additionally, economic resources and health system structures vary between countries so
attention should be focused on the particularities of each setting. In Kyrgyzstan and Uganda,
primary care is mostly manned by mid-level providers, as opposed to Greece and Vietnam
where only medical doctors diagnose and treat children. This might partially explain the differ-
ences in diagnostic patterns and history taking. In countries with high incidence of pneumonia
and limited training of primary care workforce, a focus on adhering to IMCI or other guide-
lines that are sensitive to pneumonia but not very specific [11] may be an option. However,
since most pneumonia and asthma deaths occur in these countries, [2, 12] it seems crucial to
develop tools and simple decision support approaches to help health professionals distinguish
the most common causes of acute lower respiratory illnesses and refine the differential respira-
tory diagnosis in young children by studying local etiology of ARI.
Also, over-burdened yet under-staffed facilities may serve to explain the short time of respi-
ratory consultations observed in Uganda and Vietnam. In such circumstances, important
aspects of clinical practice may be omitted in a bid to ‘clear’ patient queues. In Uganda, the
chest was often not exposed during clinical examination, a finding similar to that of a study
from Tanzania [24], leaving health professionals at risk of missing important markers of severe
disease. Increasing the focus on enhancing healthcare workforce and strengthening health sys-
tems in accordance with the Sustainable Development Goals [33] should be a priority that
could facilitate the conduction of consultations with proper history taking and clinical exami-
nation [5], factors that are critical for diagnosing respiratory illnesses in children.
The findings of this descriptive study add evidence to the worrying perspective that the
quality of clinical assessment for children with respiratory symptoms does not seem to have
improved much over the past decade. The deficiencies observed and the differences docu-
mented among countries may provide ground for further research to understand the role of
potential underlying contextual factors such as culture and quality of doctor-patient relation-
ship, validate trends and inform future interventions.
Conclusion
There seems to be substantial space for improvement in the management of children under
five years of age with respiratory disease in primary care of low-and- middle-, as well as high-
income countries. Our study has documented evidence of antibiotic overuse and frequent
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symptom relief from short-acting β-agonist trials. In countries where diagnosis and treatment
of under-fives is done by medical doctors, a focus on increasing education in good antibiotic
stewardship and raising awareness regarding differential respiratory diagnosis (including
asthma) seems to be crucial. In low-resource settings relying on guidelines to assist primary
care providers, a focus on supporting them in performing appropriate history taking and clini-
cal examination by making available delivery devices, clinical decision support applications
and essential medications, may constitute important future actions. Strengthening health sys-
tems and re-enforcing human resources also seem imperatively needed.
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